https://oncdata.com/article/b610da7a-9e63-4ab6-a349-fd5efdeb7b9fOncology Data Advisoren2026-11-11T22:49:56.585ZENETS Position Statement on Somatostatin Analogue Management in Advanced Neuroendocrine Neoplasms https://oncdata.com/article/ee5ebc20-0a45-4f31-a36c-f9b56025a143Oncology Data Advisoren2026-11-11T22:49:56.405ZPhase III DIAMOND-2 Trial: Dirozalkib vs Crizotinib in Advanced ALK-Positive NSCLC https://oncdata.com/article/8168c585-e20f-468d-8eb8-864dc2839431Oncology Data Advisoren2026-11-11T12:49:45.553ZMTAP Loss Prevalence and PRMT5 Inhibitor Activity in Oncogene-Driven and Oncogene-Negative NSCLC https://oncdata.com/article/9e3f3541-7d7f-4fb5-ad51-571e36159cb4Oncology Data Advisoren2026-11-11T12:49:45.450ZGuidelines for Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia https://oncdata.com/article/3c98794f-0635-421f-ad72-6b55a6b81149Oncology Data Advisoren2026-11-11T02:49:21.123ZPatients With Refractory iMCD May Respond to a Second IL-6 Inhibitor https://oncdata.com/article/282436ab-b63e-4ecf-be3e-8aef6bab55efOncology Data Advisoren2026-11-11T02:49:21.004ZCSCO and ASCO Joint Guideline for Recurrent and Metastatic Nasopharyngeal Carcinoma https://oncdata.com/article/9dabccd8-46d6-4b2b-9a8e-2951de04dd6fOncology Data Advisoren2026-11-10T22:49:20.566ZOptimizing Immune Checkpoint Inhibitor Selection in Metastatic Clear-Cell Renal Cell Carcinoma https://oncdata.com/article/7d132b44-ced4-46d7-b12b-fc88f3d47321Oncology Data Advisoren2026-11-10T22:49:20.448ZHER2-Directed Therapy in Biliary Tract Cancer https://oncdata.com/article/bdf70ef0-36e9-47ab-89c0-3ce7fca80d28Oncology Data Advisoren2026-11-10T12:49:20.623ZNo Significant PFS Benefit With Imlunestrant in Chinese EMBER-3 Cohort https://oncdata.com/article/e44faeb9-3036-4f8a-8595-4b0d269bc8e8Oncology Data Advisoren2026-11-10T12:49:20.525ZModeling Projects Longer PFS With DVRd in Newly Diagnosed Multiple Myeloma